Comparative Pharmacology
Head-to-head clinical analysis: NOVAFED versus SUDAFED 24 HOUR.
Peer-Reviewed Evidence
Head-to-head clinical analysis: NOVAFED versus SUDAFED 24 HOUR.
NOVAFED vs SUDAFED 24 HOUR
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Novafed contains pseudoephedrine, a sympathomimetic amine that acts as a decongestant by stimulating alpha-adrenergic receptors in the respiratory tract mucosa, causing vasoconstriction and reducing nasal congestion.
Pseudoephedrine is a sympathomimetic amine that acts as a decongestant by stimulating alpha-adrenergic receptors in the respiratory tract mucosa, causing vasoconstriction and reducing nasal congestion.
1-2 capsules orally every 12 hours; each capsule contains pseudoephedrine HCl 120 mg and dextromethorphan HBr 30 mg.
120 mg orally every 24 hours (extended-release tablet).
None Documented
None Documented
Terminal elimination half-life: 4-8 hours (mean 5-6 hours); prolonged in renal impairment (up to 20 hours) and with urinary alkalinization; in patients with normal renal function, steady-state is achieved after 2-3 days of every-6-hour dosing.
Terminal elimination half-life 9-16 hours (mean 11 hours) in adults; prolonged in renal impairment (up to 24-30 hours in severe insufficiency); clinically relevant for dosing interval (every 24 hours)
Renal elimination of unchanged drug and metabolites; approximately 60-70% of a dose is excreted in urine as unchanged pseudoephedrine within 24 hours; the remainder is metabolized hepatically and excreted renally; minimal biliary/fecal elimination (<5%).
Renal 70-90% unchanged; minor hepatic metabolism to inactive metabolites; biliary/fecal excretion negligible (<5%)
Category C
Category C
Decongestant
Decongestant